The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer therapy. In a new commentary published in Cancer Cell, Moffitt Cancer Center scientists provide a comprehensive overview of the therapy’s development and highlight its transformative potential.
2024
Presurgical Targeted Therapy, Immunotherapy Show Responses in Melanoma
Researchers have found that among patients with certain melanoma, presurgical targeted therapy and immunotherapy can result in better pathologic response.
Some melanoma cancer cells may punch their way through the body
Imagine tiny fists punching their way through your body.
Study Takes a Closer Look at Eye Cancer’s High Rate of Metastasis
Uveal melanoma is a rare cancer type with an incidence of 7.6 per million adults in Australia and represents around 5% of all melanomas.